期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多肽和蛋白质药物的吸入给药 被引量：4

Inhalation Delivery of Peptide and Protein Drugs
下载PDF
导出
摘要 概述了多肽和蛋白质药物的肺吸收机制和用于吸入给药的研究进展,并简要讨论了多肽和蛋白质药物在用于吸入给药时存在的问题及今后的发展方向,为多肽和蛋白质药物的吸入给药研究提供一定的参考。 It is reviewed about the pulmonary absorption mechanism and inhalation delivery of peptide and protein drugs.The problem and prospect of pulmonary delivery of peptide and protein drugs are also briefly discussed to provide a reference for their inhalation study.
作者 邹红霞 程洪亮 李京京 刘秋焕 陆兵
机构地区 军事医学科学院生物工程研究所
出处 《生物技术通讯》 CAS 2011年第6期897-900,共4页 Letters in Biotechnology
关键词 多肽 蛋白质 吸入 peptide protein inhalation
分类号 R94 [医药卫生—药剂学] Q51 [生物学—生物化学]
  • 相关文献

参考文献33

  • 1Agu R U, Ugwoke M I, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides [J]. Respir Res, 2001,2(4):198-209.
  • 2Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecule principles, problems, and examples[J]. J Physiol Pharmacol, 2008,59(Suppl 6):53-79.
  • 3Patton J S. Mechanisms of macromolecule absorption by the lungs[J]. Adv Drug Del Rev, 1996,19(1):3-36.
  • 4Kobayashi S, Kondo S, Juni K. Permeability of peptides and proteins in human cultured alveolar A549 cell monolayer [J]. Pharm Res, 1995,12(8):1115-1119.
  • 5Siekmeier R, Scheuch G. Treatment of systemic diseases by inhalation of biomolecule aerosols [J]. J Physiol Pharmacol, 2009,60(Suppl 5):15-26.
  • 6Folkesson H G, Westrom B R, Dahlbaek M, et al. Passage of aerosolized BSA and the nona-peptide dDAVP via the respiratory tract in young and adult rats[J]. Exp Lung Res, 1992,18 (5):595-614.
  • 7Adjei A, Sundberg D, Miller J, et al. Bioavilability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans[J]. Pharm Res, 1992,9(2):244-249.
  • 8Shahiwala A, Misra A. A preliminary pharmacokinetie study of liposomal leuprolide dry powder inhaler: a technical note [J]. AAPS Pharm Sci Tech, 2005,6:E482-E486.
  • 9Zijlstra G S, Hinrichs W L, de Boer A H, et al. The role of particle engineering in relation to formulation and deagglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix [J]. Eur J Pharm Sci, 2004,23(2): 139-149.
  • 10Lizio R, Klenner T, Sarlikiotis A W, et al. Systemic delivery of cetrorelix to rats by a new aerosol delivery system[J]. Pharm Res, 2001,18(6):771-779.

二级参考文献40

  • 1叶伟民,韩焕兴,范列英,孔宪涛.Bradford比色法简便、快速测定微量蛋白[J].上海医学检验杂志,1996,11(4):207-208. 被引量：26
  • 2Rosenstock J, Cappelleri JC, Bolinder B, et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes [J].Diabetes Care, 2004, 27 (6): 1318 -1323.
  • 3Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insu lin therapy in patients with type 2 diabetes: results of a 6- month, randomized, comparative trial [J]. Diabetes Care, 2004, 27 (10): 2356-2362.
  • 4Weiss SR. Cheng SL, Kourides IA, et al. Inhaled Insulin Phase II Study Group; Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately comtrolled with oral agents: a randomized controlled trial [J].Arch Intern Med, 2003, 163 (19): 2277- 2282.
  • 5Ceglia L, Lau J, Ptiias AG. Meta analysis: efficacy and safety of inhaled insulin therapy in aduhs with diabetes mellitus[J]. Ann Intern Med, 2006, 145 (9): 665 -675.
  • 6Wise S, Chin J, Yeo K, et al. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly Dura inhaled insulin [J]. Diabet Med, 2006, 23 (5): 510 -515.
  • 7Rosenstock J, Cefalu WT, Hollander PA, et al. Two year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes [J].Diabetes Care, 2008, 31 (9): 1723-1728.
  • 8Mack GS. Pfizer dumps Exubera.[J]. Nat Biotechnol, 2007, 25 (12): 1331- 1332.
  • 9Harper NJ, Gray S, De Groot J, et al. The design and per formance of the exubera pulmonary insulin delivery system [J]. Diabetes Technol Ther, 2007. 11 (9): S16- 27.
  • 10Barnett AH, Bcllary S. Inhaled human insulin (Exubera): clinical profile and patient considerations [J]. Vasc Health Risk Manag, 2007, 3 (1): 83-91.

共引文献2

同被引文献49

  • 1陈桂良,侯惠民.以氯氟烃(CFC)和氢氟烷(HFA)为抛射剂的沙丁胺醇气雾剂的特性比较[J].药物分析杂志,2006,26(1):144-147. 被引量：9
  • 2陈桂良,侯惠民.HPLC荧光检测法测定大鼠肺中沙丁胺醇浓度及其在肺部给药中的应用[J].药物分析杂志,2006,26(7):934-937. 被引量：2
  • 3陈桂良,侯惠民.吸入用气雾剂雾粒测定方法的评价[J].中国医药工业杂志,2007,38(3):194-199. 被引量：24
  • 4Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for sys- temic delivery of therapeutic proteins and peptides. Respir Res,2001, 2(4) :198.
  • 5LIXiao-ling(李霄凌).DesignofControlledReleaseDrugDelivery Systems(控释药物传递系统的设计).Beijing(北京):ChemicalIndustrialPress(化学工业出版社),2008.
  • 6Antti A, Mika L, Marjut RP. Patient satisfaction with Easyhaler com- pared with other inhalation systems in the treatment of asthma : A me- ta - Analysis. Curr Ther Res ,2000,61:61273.
  • 7Robsamen R. Novel aerosol peptide drug delivery systems. In:Adjei AL, Gupta PK Eds. Inhalation Delivery of Therapeutic Peptides and Proteins. New York : Marcel Dekker, 1997. 722.
  • 8Bakand S, Hayes A, Dechsakuhhom F. Nanoparticles: a review of particle toxicology following inhalation exposure, lnhal Toxicol, 2012,24(2) :125.
  • 9Heinemann L, Klappoth W, Rave K, et al. Intra - Individual variabil- ity of metabolic effect of Inhaled Insulin together with an absorption enhancer. Diabetes Care,2000,23 (9) : 1343.
  • 10Schlesinger RB, Naumann BD, Chen LC. Physiological and histologi- cal alterations in the bronchial mucociliary clearance system of rab- bits following intermittent oral or nasal inhalation of sulfuric acid mist. J Toxicol Environ Health, 1983,12 (2 - 3 ) :441.

引证文献4

二级引证文献22

生物技术通讯
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部